Mark J. Holterman, Medical

ADA and CHLA Team Up to Tackle Type 2 Diabetes in Young People


 CHLA pic

A medical school graduate of the University of Virginia, Mark Holterman, MD, teaches surgery and pediatrics at the University of Illinois College of Medicine. Committed to the advancement of medicine and finding a cure for chronic health conditions such as diabetes, Dr. Mark Holterman belongs to the American Diabetes Association (ADA).

In early September, the ADA announced a joint initiative with Children’s Hospital Los Angeles to address the increasing rate of type 2 diabetes occurring in children and teenagers. The two organizations have developed an experience called Camp PowerUp, which utilizes an evidence-based curriculum to engage youth in physical activities and teach them how to make healthier food choices, in order to lower their risk of developing type 2 diabetes.

The program will target young people between the ages of eight and 16 in a range of settings, from day camps and after-school programs to churches and parks. With the experience that the two organizations bring to the table in terms of diabetes care and childhood medicine, they believe programs such as this can help stop the rise of type 2 diabetes in this vulnerable age group.

Mark J. Holterman, Medical

21st Century Cures Act Supports Regenerative Medicine


21st Century Cures Act pic
21st Century Cures Act

Mark Holterman, MD, a pediatric surgeon, has served as a member of the general surgical team at Children’s Hospital at OSF Healthcare since 2011. He is additionally a professor in the Division of Pediatric Surgery at the University of Illinois College of Medicine in Peoria. Dr. Mark Holterman, CEO of regenerative medicine-focused Mariam Global Health, maintains a strong interest in the development of cell-based therapies.

In late 2016, the United States Congress passed and President Obama signed the 21st Century Cures Act. This legislation, the result of bi-partisan alliances in Congress, was designed to help patients with serious health conditions benefit from the fast-tracking of new drugs and medical devices. It also channels new funds into medical research. In addition to its $2 billion designated over a two-year period to fight the American opioid epidemic, and other provisions, the law provides greater support to the field of regenerative medicine.

The act builds on the Food and Drug Administration’s recent practice of incorporating the input of patients into the agency’s drug approval procedures. Thus, it provides for a quicker and more efficient FDA approval process for certain stem cell treatments before they enter the market. The membership of groups such as the World Stem Cell Summit and the Alliance for Regenerative Medicine applauded the new legislation.

Mark J. Holterman, Medical

ADA and APA Join Hands in Training Mental Health Professionals


ADA and APA  pic

Mark Holterman, MD received his degree in medicine and immunology from the University of Virginia. He currently serves as a professor of surgery and pediatrics at the University of Illinois College of Medicine. Dr. Mark Holterman is a member of several professional organizations including the American Diabetes Association (ADA).

Founded in 1940, ADA is a leading non-profit organization that concentrates on conducting research, education, and advocacy activities related to the treatment, prevention, and cure of diabetes. The organization sponsors several programs to support its mission, some of which are collaborative efforts with other organization. One of these programs is the Mental Health Provider Diabetes Education Program, a joint effort with the American Psychological Association.

The program aims to serve the need for mental health professionals who are willing to cater to the psychosocial challenges associated with diabetes management. It is a two-part continuing education program that requires interested practitioners to complete a seven-hour face-to-face seminar and a five-hour online course. Upon successful completion of the courses, providers will be listed on the ADA website which can be freely accessed by those seeking treatment. This program launched in June of this year and has recently received a $839-million grant from the Helmsley Charitable Trust.

Mark J. Holterman, Medical

Treatment Goals for SJIA


Dr. Mark J. Holterman pic
Dr. Mark J. Holterman

Yale University alumnus Mark Holterman, MD is a successful pediatrician and surgeon with over two decades of experience. He currently holds a full professorship position at the University of Illinois College of Medicine where he is an active surgeon inthe division of pediatric surgery. Dr. Mark Holterman was one of the minds behind the establishment of non-profit organization The Hannah Sunshine Foundation.

The Hannah Sunshine Foundation is an organization that focuses on the use of cellular and regenerative therapies for children with rare diseases. It was inspired by three young people, one of which was Sarah Hughes, a 23-year-old woman afflicted with systemic juvenile idiopathic arthritis (SJIA).

SJIA is a serious subtype of juvenile idiopathic arthritis (JIA). Unlike other types of JIA, the condition not only affects the joints but also involves other organs such as the heart, liver, and lungs. The condition is rare and only occurs among 10 to 20 percent of all children who have some form of JIA.

The disease has no known cure as of yet, but treatment is available. Doctors managing the disease focus on achieving permanent remission – a state wherein there are no clinical signs and symptoms that the disease is still active. Due to the damage that it may bring the joints, experts believe that early, aggressive treatment during the active phase of the disease should be encouraged.

Mark J. Holterman, Medical

The American Diabetes Association’s Two Research Awards


American Diabetes Association pic
American Diabetes Association

Mark Holterman, MD, has practiced pediatric surgery and studied regenerative medicine for several years. The CEO of Mariam Global Health, he splits his time between medical research, teaching surgery at the University of Illinois, and providing pediatric care to surgical patients at OSF St. Francis Medical Center. As testament to his successes in the field, Dr. Mark Holterman has earned several awards, including the Innovative Research Award from the American Diabetes Association, an organization committed to funding research into diabetes cures and prevention measures.

The American Diabetes Association offers two research awards to professionals: the Innovative Basic Science (IBS) award and the Innovative Clinical or Translational Science (ICTS) award.

Available to faculty members at any level, the IBS award is given to basic research that presents an innovative and new hypothesis. These hypotheses must be related to the pathophysiology or etiology of diabetes and demonstrate significant progress in terms of advancing diabetes treatment and prevention. The organization specifically encourages high-risk projects that have a larger potential for producing high-impact results.

Eligible applicants are authorized to work in the United States, and IBS award recipients receive up to $115,000 per year for a maximum of three years.

Meanwhile, the ICTS award grants recipients $200,000 per year for up to three years. This award is also limited to professionals who are authorized to work in the country, and it is given to research that presents innovative hypotheses and demonstrates a high probability of high-impact results. However, ICTS award recipient research must directly involve human data, samples, or subjects.

Mark J. Holterman, Medical

About Mesenchymal Stem Cells


Celltex pic

Mark Holterman, MD, teaches coursework in surgery and pediatrics as a professor at the University of Illinois College of Medicine at Peoria. An expert in cellular and regenerative therapies, Dr. Mark Holterman also helped to found the Alliance for the Advancement of Cellular Therapies and the Sunshine Foundation.

A charitable organization, the Sunshine Foundation was created to support cellular and regenerative therapies. It was inspired by three young individuals who received effective cellular and regenerative therapies. Celltex Therapeutics, a biotechnology firm, provided regenerative therapy for one of the individuals to treat systemic juvenile idiopathic arthritis and dysautonomia.

Celltex utilizes stem cells known as mesenchymal stem cells when conducting cellular therapy. Mesenchymal stem cells, also known as MSCs, can be readily found in tissue throughout the human body. Fat tissue is a plentiful source for MSCs, but they are often taken from bone marrow, umbilical cord blood, and placenta tissue as well.

MSCs have the ability to grow into many different cell types, such as bone and muscle, and play a role in combating inflammation, improving healing, stopping cellular decay, and forming new blood vessels. For additional information, visit

Mark J. Holterman, Medical

The Xvivo System’s Modular Design


Xvivo System pic
Xvivo System

Pediatric surgeon Mark Holterman, MD, has over two decades of experience. At present, Dr. Mark Holterman applies his expertise as a professor at the University of Illinois College of Medicine at Peoria and as an attending physician at OSF Saint Francis Medical Center, where he was co-surgeon on the first trachea transplant in a small child ever completed.

A nine-hour operation, the transplant was performed on a 32-month-old Korean toddler who was born without a developed trachea. In addition to extensive clinical and scientific expertise, the operation relied on an engineered stem cell-based trachea, a nanofiber tracheal scaffold and bioreactor, and the Biospherix Xvivo cell incubation and processing system.

The Xvivo is a closed system, featuring closed hoods and closed cell incubators, that enables the growth and storage of cell cultures. The system, which is modular, can be configured in hundreds of different ways. For example, the simplest format (stage 1) might feature a single closed hood and a single incubator. Stage 2 could add an additional incubation chamber, a microscope station, and other third-party add-ons such as a cell separator. The third stage could include an unlimited number of additional incubators while also incorporating more hoods and other stations.